OTS - Joint against malaria: European Investment Bank, European Commission and Investitionsbank Berlin inaugurate €70 million fund
2020. June 03. 15:30
Berlin, Luxembourg, 3 June, 2020 (APA/OTS) - Today, the European
Investment Bank (EIB), the European Commission and Investitionsbank
Berlin (IBB) announced the first closing of their EU Malaria Fund
(https://www.controlmalaria.eu/). The European Commission and the
European Investment Bank are investing an initial EUR 64 million
into the fund, which aims to bridge the gap between molecule and
market for feasible and affordable innovative solutions to prevent
and treat malaria. It is complemented by investment from IBB, the
Bill & Melinda Gates Foundation, Fondazione Monte Dei Paschi Di
Siena, Jacques und Gloria Gossweiler Stiftung, Invethos AG, FINDdx,
and Novartis AG.
"If we are lucky, our fund can be a life-saver for hundreds and
thousands of people every year." said Ambroise Fayolle, EIB Vice
President in charge of health.
Mariya Gabriel, European Commissioner for Innovation, Research,
Culture, Education and Youth, said: "We are joining forces with
other investors to protect health and save lives. The new EU
Malaria Fund is working with a total EU contribution of more than
€110 million to boost research efforts and speed up market
solutions against this preventable and deadly disease. This is an
example of how key global players can come together to fight
infectious diseases such as malaria and bring health technologies
to those who need them most."
"We're looking forward to working closely with our partners to
find innovative solutions to prevent and treat malaria in the
future," said Dr. Jürgen Allerkamp, Chairman of the Board,
Investitionsbank Berlin
(https://www.ibb.de/en/homepage/homepage.html).
"This is a decisive instrument that could potentially be
leveraged in other disease areas with similar underlying market
failure," adds Holm Keller, Chairman of kENUP Foundation
(https://www.kenup.eu/) and Managing Director of the EU Malaria
Fund.
The instrument will finance companies through venture debt. The
first two investments earmarked by the fund are expected to go to
Italian AchilleS Vaccines https://www.achillesvaccines.com/) and to
Austrian Themis Bioscience GmbH (https://www.themisbio.com/).
Press Contact
Tobias Mac-Lean
+4915116744480
maclean@kenup.eu
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.